Beiträge
Randomized Controlled Immunotherapy Clinical Trials for GBM Challenged
/in Dendritic Cells, Glioblastoma, Hyperthermia, International Publications, Newcastle Disease Virus /von 2020-12-24 / Cancers (Basel) 2020 Dec;13(1)Evidence-Based Medicine in Oncology: Commercial Versus Patient Benefit
/in Dendritic Cells, Hyperthermia, International Publications, Newcastle Disease Virus /von 2020-07-23 / Biomedicines 2020 Jul;8(8)Position paper: new insights into the immunobiology and dynamics of tumor-host interactions require adaptations of clinical studies
/in Dendritic Cells, Glioblastoma, Hyperthermia, International Publications, Newcastle Disease Virus /von 2020-06-30 / Expert Rev Anticancer Ther 2020 Aug;20(8):639-646Addition of Multimodal Immunotherapy to Combination Treatment Strategies for Children with DIPG: A Single Institution Experience
/in Brain Tumors in Children, Dendritic Cells, Hyperthermia, International Publications, Newcastle Disease Virus /von 2020-05-19 / Medicines (Basel) 2020 May;7(5)Consensus guidelines for the definition, detection and interpretation of immunogenic cell death
/in Dendritic Cells, International Publications, Newcastle Disease Virus /von 2020-03-01 / J Immunother Cancer 2020 Mar;8(1)Breaking Therapy Resistance: An Update on Oncolytic Newcastle Disease Virus for Improvements of Cancer Therapy
/in Checkpoint-Inhibitors, Dendritic Cells, International Publications, Newcastle Disease Virus /von 2019-08-30 / Biomedicines 2019 Aug;7(3)Immune Phenotype Correlates With Survival in Patients With GBM Treated With Standard Temozolomide-based Therapy and Immunotherapy
/in Dendritic Cells, Glioblastoma, International Publications /von 2019-04-01 / Anticancer Res. 2019 Apr;39(4):2043-2051Immunotherapy in atypical teratoid-rhabdoid tumors: Data from a survey of the HGG-Immuno Group
/in Brain Tumors in Children, Dendritic Cells, International Publications /von 2016-07-12 / Cytotherapy 2016 09;18(9):1178-86Dendritic cell vaccines based on immunogenic cell death elicit danger signals and T cell-driven rejection of high-grade glioma
/in Dendritic Cells, Glioblastoma, International Publications /von 2016-03-02 / Sci Transl Med 2016 Mar;8(328):328ra27
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Neu in der Corona Ambulanz Köln: PCR Schnelltest
- Vitamin D supplementation to the older adult population in Germany has the cost-saving potential of preventing almost 30,000 cancer deaths per year
- Efficacy of a curcumin extract (Curcugen™) on gastrointestinal symptoms and intestinal microbiota in adults with self-reported digestive complaints: a randomised, double-blind, placebo-controlled study